SpineThera to Present at WVSIPP Incube Meeting in Conjunction with ASPN Think Tank

March 9, 2022

SpineThera to Present at WVSIPP Incube Meeting in Conjunction with ASPN Think Tank

Medical Alley, Minnesota, united states, March 9, 2022 – SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that Jeff Missling, Chief Executive Officer, will be presenting at the InCube meeting hosted by the West Virginia Society of Interventional Pain Physicians (WVSIPP) in Nashville, TN on March 13, 2022.  InCube is being held in conjunction with the American Society of Pain and Neuroscience (ASPN) Think Tank meeting.

Jeff Missling, CEO, stated, “We thank Dr. Rudy Malayil, President of WVSIPP, for the invitation to present at the Incube meeting, a showcase of emerging companies with novel approaches addressing pain.  SpineThera’s SX600 utilizes SpineThera’s proprietary micro-suspension platform technology that enables a highly concentrated injection of sustained-release formulations.  Its application in lumbar radiculopathy has the potential to provide longer-term pain relief from a single injection.  I look forward to presenting our technology to this group of thought leaders at the InCube meeting.”

###

About SpineThera
SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its proprietary and differentiated sustained-release platform technology. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. The company’s lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for lumbar radiculopathy. SpineThera, Inc., is based is Medical Alley, Minnesota, the global epicenter of health innovation and care. SpineThera Australia Pty Ltd is a wholly owned subsidiary of SpineThera, Inc., and is the sponsor of the SALIENT study.

Press Contact
info@spinethera.com

October 5, 2023

SpineThera Celebrates Milestone Achievement with 6th Patent Issued by the US Patent and Trademark Office

PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced United States Patent and Trademark Office (USPTO) has issued Patent No. 11,771,707 related to its micro-suspension platform technology.
September 25, 2023

SpineThera SALIENT Clinical Trial Results to Be Presented at Upcoming 22nd Annual ASRA Pain Medicine Meeting

PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced that the submitted abstract,” Clinically Meaningful Radicular Leg Pain Management via Novel Dexamethasone Extended Release Microsuspension (SX600)- PH1/2 Results” has been accepted for presentation at the 22nd Annual Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine (ASRA).
September 6, 2023

SpineThera Announces Breakthrough Market Research Results for SX600 in the Management of Sciatica Pain

SpineThera, Inc. announces groundbreaking market research indicating a potential 70% market adoption of its flagship investigational drug SX600.

Proven health impact

SpineThera produce more effective health-benefit leads, with a higher hit rate, in less time than any other method available today.